Routine primary care data for scientific research, quality of care programs and educational purposes: the Julius General Practitioners’ Network (JGPN)

Hugo M. Smeets1, Marlous F. Kortekaas1*, Frans H. Rutten1,2, Michiel L. Bots1, Willem van der Kraan3, Gerard Daggelders4, Hanneke Smits-Pelser5, Charles W. Helsper1, Arno W. Hoes1 and Niek J. de Wit1,5

Abstract
Background: General Practitioners (GPs) in the Netherlands routinely register all patient contacts electronically. These records include longitudinally gathered clinical information of the patient contacts in coded data and free text.

Methods: Diagnoses are coded according to the International Coding of Primary Care (ICPC). Drug prescriptions are labelled with the Anatomical Therapeutic Chemical Classification (ATC), and letters of hospital specialists and paramedic health care professionals are linked or directly incorporated in the electronic medical files. A network of a large group of GPs collecting routine care data on an ongoing basis can be used for answering various research questions.

Results: The Julius General Practitioners’ Network (JGPN) database consists of routine care data from over ten years of a dynamic cohort of around 370,000 individuals registered with the participating GPs from the city of Utrecht and its vicinity. Health care data are extracted anonymously every quartile of a year and these data are used by researchers.

Conclusion: We describe the content and usability of our JGPN database, and how a wide variety of research questions could be answered, as illustrated with examples of published articles.

Keywords: Electronic medical record, Quality of care, Database, Research, ICPC

Background
The Dutch health system is based upon a gatekeeper system, in which patients only have access to hospital care after consulting the general practitioner (GP). All Dutch residents are registered with a GP, and all have mandatory health care insurance. GPs provide basic care for all health problems for all patient categories; emergency care, chronic disease, and mental health problems. GP care is completely insured and is not subject to initial payment; therefore the threshold for consultation is low. GP registries therefore adequately reflect morbidity patterns of the Dutch population, as far as it results in a contact with a healthcare provider.
registration databases in many countries [4, 9]. Primary care research networks originated from local systems improved registration uniformity and made records in terms of completeness and accuracy [8]. In more recent years, routine care databases also proved suitable for the monitoring of quality of care in general practice. In the UK, GPs within the National Health Service (NHS) monitor relevant quality parameters with standardized templates as part of the routine clinical process. In the Netherlands, GP network organisations initiated coding and monitoring of chronic disease management, which further improved the quality of the records in terms of completeness and accuracy [8].

Routine care databases are widely used for research. Primary care research networks originated from local initiatives, but in recent years they have expanded to large-scale registration databases in many countries [4, 9–11]. In the UK, the General Practice Research Database (GPRD) has been shown to be an effective environment for large scale observational research in primary care. Catalonia (SIDIAIP), Scotland (ESCR0), and Canada (CPSNN) also provide comparable databases enabling research.

Academic research in routine primary care databases in the Netherlands has a longstanding tradition. In the 1960s a number of dedicated general practitioners in the Nijmegen area started the Continuous Morbidity Registration (CMR), which at present has more than 40 years of follow-up registration data of 15,000 patients [12, 13]. In 1970 in the Amsterdam region, Lambers introduced the ICP coding system in the Netherlands, initiated in ‘the Transition project’; reasons for encounter and (working) diagnoses were uniformly coded [14–16]. In 1998, The Netherlands Institute for Primary Care (Nivel) conducted the first national survey of general practices, resulting in a countrywide registry of presented morbidity, and diagnostic and therapeutic interventions in primary care. In follow-up, the NIVEL set up a permanent representative nationwide network of sentinel practices (LINH), which produces regular monitoring reports on epidemiology, management and organization of general practice in the Netherlands [17].

In the Utrecht region, six general practice groups collaborating with the University Medical Centre started in 1996 a registration network, with the mission to make their routine care data accessible for research [18]. With developing registration systems and training in systematic data recording, the data quality improved over the years, and this academic primary care network became a high-quality cohort for research. In 2016 the network had expanded to 64 practices, and presently consists of routine primary care data of 370,000 enlisted individuals (see Table 1), with 1.38 million consultations annually, and 15–20 years follow-up.

In this paper we describe the organisation and data content of the Julius General Practitioners’ Network (JGPN), the different types of research that have been performed with the data and the potential of the networks for future innovation and how the data can be supportive in education in general practice.

Methods
Aims and objectives of the JGPN
The main aims of JGPN are to facilitate clinically relevant research, the development of health care innovations and to support quality management by using routine care data. The network infrastructure brings together routine care registration data from all participating practices. After obtaining consent from a scientific board, the anonymised database can be used for scientific research. The network can generate key indicators of clinical performance of participating practices that can be benchmarked with the rest of the network. The network also supports innovative disease management programs, such as panel management of frail elderly and early identification of patients at risk of depression and cardiovascular disease. In the near future, the network data will be used to monitor the educational progress of GP trainees working in the network practices.

Organisation and infrastructure
Demographics
The current composition of the patient database, and the geographical distribution of the participating practices in urban and (semi) rural regions make the JGPN population representative for the Dutch population. Gender, mean age, and age distribution of patients is comparable to the Dutch population (47.9% versus 49.5% males, 39.5 vs. 41.3 years; Table 1). The number of participating female GPs is higher than the Dutch average (60% vs. 44%), as is the number of group practices in JGPN (76% vs. 33% national average). Median follow-up time in the present JGPN is 6.4 years (IQR 2.4–14.1), with a median follow-up time per practice (N = 67) of 8.6 years (IQR 7.4–11.8). Minimum follow-up time is 0 years, maximum 87.8 years. The mean loss to follow-up in the network over the years is 5.3% annually, mainly caused by moving as a result of enlistment to another GP who is not participating in the JGPN network. In 2015, the average number of diagnoses and prescriptions per patient was 2.3 (range 0–45), and 2.5 (range 0–96), respectively. Patients contacted their GP on average 3.7 times per year (range 0–193), with 30% of patients not visiting their GP.
The data

The JGPN-database contains structured information of each patient-doctor consultation in the participating practices. This makes it possible to follow the ‘health career’ of the individual patient. All contacts are registered according to a systematic format with information on symptoms, signs, diagnostic test results, diagnosis, and patient management, including drug prescription and referral to hospital specialists. Diagnoses are entered according to ICPC coding, hospital referrals are coded according to specialist and prescribed medication (including dose) is entered in ATC (anatomical therapeutic coding). In addition, GP consultations are grouped in episodes, i.e. a series of consultations related to a single reason for encounter (a symptom or a diagnosis). In 2015, for example, the database contained 11,547 new episodes of diabetes mellitus and 22,330 new or recurrent episodes of upper respiratory tract infections (Table 1). Return letters from hospital specialists are received electronically, and linked manually by the GP to the ICPC coded episodes in the EMR. Frequently GPs copy paste a summary and conclusions of letters in free text boxes of the EMR. Every three months the database is uploaded with the data extractions from the participating practices.

Data quality

In general, completeness and accuracy of routine databases depend on the systematic registration of the

| Number of general (group) practices | Total number of patients enlisted | Average number of contacts per day per practice | Total number of patient contacts per year | Mean number of patient contacts per year (range) |
|-----------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| 64                                | 371,028                         | 79.9                           | 1384.129                        | 3.7 (0–193)                     |

| Age groups in years | Number of contacts | Number of contacts (%) of total | Mean number of prescriptions per patient | Mean number of prescriptions with just one prescription (%) | Percentage of patients in the Netherlands with the prescription |
|---------------------|--------------------|---------------------------------|----------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| 0–19                | 41,405 (11)        | 39,700 (11)                     | 4,1                                    | 12,619 (32)                                               | 16                                                      |
| 20–39               | 50,722 (14)        | 60,717 (16)                     | 5,1                                    | 3183 (12)                                                 | 11                                                      |
| 40–59               | 51,256 (14)        | 51,238 (14)                     | 5,6                                    | 3207 (15)                                                 | 10                                                      |
| > 60                | 33,965 (10)        | 40,845 (11)                     | 5,9                                    | 3689 (17)                                                 | 9                                                       |

| Top five prescribed drugs according to the Anatom-Therapeutic Codes (ATC) for medication | Number of prescriptions (% of total) | Mean number of prescriptions per patient | Number of patients with just one prescription (%) | Percentage of patients in the Netherlands with the prescription |
|-----------------------------------------------------------------------------------------------|--------------------------------------|----------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Antacids (PPI’s, H2-antagonists, and antacids) (A02B)                                        | 164,293 (7)                          | 39,613 (11)                             | 4,1                                              | 12,619 (32)                                               | 16                                                      |
| Statins and other cholesterol lowering drugs (C10A)                                          | 134,352 (5)                          | 26,24 (7)                               | 5,1                                              | 3183 (12)                                                 | 11                                                      |
| Antithrombotics (Vitamin K antagonists, NOACs, and anti-platelets) (B01A)                    | 123,209 (5)                          | 22,195 (6)                              | 5,6                                              | 3207 (15)                                                 | 10                                                      |
| Beta-blockers (C07A)                                                                         | 105,737 (4)                          | 21,413 (6)                              | 4,9                                              | 3689 (17)                                                 | 9                                                       |
| Antidepressants (N06A)                                                                        | 100,883 (4)                          | 18,046 (5)                              | 5,6                                              | 3048 (17)                                                 | Below top 10                                               |

| Top five diagnoses according to the International Code Primary Care (ICPC) for diagnoses | Number of contacts with such an ICPC-labelled diagnosis | Percentage of total number of contacts with an ICPC-code (%) | Mean number of contacts per patient (minimum-maximum) | Percentage of patients in the Netherlands with the ICPC-code |
|------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------|
| Hypertension (K86, K87)                                                                    | 52,508 (2708)                                          | 3.9                                                       | 18,445 (5)                                           | 2.8 (1–29)                                               | 4                                                       |
| Type 1 and 2 Diabetes Mellitus (T90)                                                       | 51,194 (11,547)                                       | 3.8                                                       | 11,283 (3)                                           | 4.5 (1–79)                                               | 2                                                       |
| Cystitis/urinary tract infection (U71)                                                     | 28,834 (19,495)                                       | 2.1                                                       | 12,473 (3)                                           | 2.3 (1–35)                                               | 3                                                       |
| Cough (R05)                                                                                | 25,487 (22,794)                                       | 1.9                                                       | 16,966 (5)                                           | 1.5 (1–15)                                               | 2                                                       |
| Upper respiratory tract infection (R74)                                                    | 23,579 (22,330)                                       | 1.7                                                       | 17,580 (5)                                           | 1.3 (1–13)                                               | 2                                                       |
different steps in the consultation [19, 20]. To optimize and synchronize this coding process, the JGPN management has organised coding training sessions for participating GPs from the beginning [21]. This has resulted in more systematic data registration. Nowadays, the software support is such that entering an ICPC code for every episode is mandatory in most EMRs [9, 22]. As a result, the JGPN database represents a complete and increasingly accurate reflection of the morbidity, follow-up and medical management of the enlisted patient population. The database seems to produce reliable quantitative estimates of symptom incidence, disease prevalence, referral and prescription rates, but also qualitative data on the reason for encounter and patient presentation [23–28].

**Enriching the database by data linkage**

To widen the scope of the individual health data, the JGPN database can be linked to other data sources. Specialist data can be accessed from the databases of hospitals or insurance companies. In the latter database, all secondary care interventions are stored, coded through so called ‘diagnostic therapeutic combinations (DBC) codes. In addition, linkage to national disease or mortality databases like the regional primary care laboratory, the National Cancer Registry or the National Mortality Registry, generates important complimentary sources of information [29]. Technically, data linkage with JGPN is done through a Trusted Third Party (TTP) construction using anonymised pseudo-identification, safeguarding that the patients’ identity is not disclosed to researchers. In the past JGPN data were successfully linked to a regional psychiatric database to assess potential association between somatoform disorders, infectious diseases and antibiotic prescriptions [30]. Sollie et al., managed to validate the cancer diagnoses in JGPN through linkage with the National Cancer Registry [31]. In the future, a virtual network may be constructed in which databases of daily patient encounters of different health organisations, including JGPN, will be connected, thus providing a regional data warehouse for research and quality monitoring.

**Privacy issues**

The JGPN is subject to Dutch privacy law. The law on the medical consultation (Dutch: WGBO) states that the use of medical data for scientific research is allowed provided that i) results cannot be traced to individual patients, ii) and people are adequately informed beforehand allowing them an opt out option. As a consequence, all GPs participating in JGPN inform their patients by practice flyers and/or on their internet site about the anonymous use of their medical records for research purposes. Patients may opt out, and their routine care data will not be used for the JGPN database (opt-out regulation). The law on medical research (Dutch: WMO) states that medical research on patients requires individual consent if an intervention takes place. Research in JGPN is observational, without an intervention, and enlisted patients are not individually approached for participation. Therefore, the Medical Ethics Committees in the Netherlands do not rank such research as subject to the WMO conditions, but researcher need to confirm to the privacy legislation. The complete anonymised dataset is stored safely, and only copies of parts of it are delivered to researchers after they have requested it and JGPN has agreed on executing their research proposal. Such data sets are made only available under the strict condition of anonymity, and researchers have to give written consent to destruct the data at the end of their study. Only under very strict conditions free text is made available to researchers, after free text fields are anonymised by the computer program TM7 that is especially developed for this purpose [32]. In the data linkage process privacy is ensured by the so-called pseudonymisation procedure; linkage codes are destroyed after successful data linkage.

**Governance**

All participating GP practices have a longstanding relationship with the network. In return for their willingness to participate, they receive a small annual fee or benchmark information about their practice of the listed patient population and their medical management. The operational process of the network is run by a small team consisting of a coordinating and operational manager, a data-manager and secretarial support. The use of the database for research is monitored by a steering committee, consisting of representatives of the participating GPs in the network, the operational manager, and supplemented by research advisors of the Julius Centre. As yet, patients are not included on the steering committee. This steering committee also assesses requests for data submitted by researchers following a standard procedure. Research proposals should meet pre-set criteria, including sufficient quality of methodology, clinical relevance, and acceptable burden for practices and patients of JGPN. After consent of the steering committee and signing of the JGPN contract, data management of the JGPN prepares the requested dataset. Researchers pay a fee for each dataset, and thus contribute to the maintenance costs of the JGPN dataset. Most of the running costs are covered by institutional sponsoring of the University Medical Centre Utrecht.

**Results**

**Examples of research performed in the JGPN database**

In the past 10 years the JGPN database has been used by researchers of the UMC Utrecht as well as by external research groups, which has resulted in 165 research
projects and 105 peer reviewed publications. Data have been used for descriptive research and observational studies, such as trends in antibiotic prescriptions, but also for other types of epidemiological research [33–35].

**Etiologic studies**
In etiological research, the causal relationship between a single determinant (i.e. risk factor) and a disease (or outcome) is assessed, but without randomisation the association is distorted by confounders. The most important potential confounders registered in the JGPN database include age, gender, lifestyle, socio-economic status, and co-morbidities. Additional patient characteristics can be obtained through linkage with other databases or through the use of proxy indicators. With supplementary data acquisition etiologic research is possible within the JGPN database.

**Example of etiologic research in the JGPN database**
Rutten et al. assessed the long-term effect of beta-blocker use on survival and exacerbation in patients with COPD. After correction for multiple (potential) confounders, the adjusted hazard ratios (HRs) for all-cause mortality and exacerbations were calculated with both propensity scores and Cox regression analyses. [36].

**Diagnostic studies**
Diagnostic studies usually aim to determine the diagnostic value of tests in patients suspected of a certain disease. For this type of research all suspected cases should have undergone the test(s) under investigation, but also the reference test to establish the disease (the outcome), without work-up bias. This is usually not the case in routine care data. Routine care data can however be used to identify potentially useful determinants that may be part of a diagnostic prediction model derived from a cohort with enough necessary information to perform such prediction research.

**Examples of diagnostic research in the JGPN database**
Van de Pol et al. investigated the determinants of referral for recurrent respiratory tract infections (RTI) in young children aged between zero and two years old [37]. In the study of Van Mourik et al eighteen of the JGPN practices participated. In this diagnostic cluster randomized trial opportunistic screening of 1249 frail elderly with reduced exercise tolerance was compared to care as usual for the detection and the following management of newly diagnosed heart failure and COPD [38].

**Prognostic studies**
Prognostic research focusses on prediction, answering the question; which variables predict an outcome such as mortality in patients with a certain disease, irrespective of a possible causal relation [34]. Consequently, confounding is not an issue. These studies are usually performed within a well-defined cohort of patients followed for a period of time to facilitate development of disease. It requires the presence of data of the patient’s condition and of potential determinants, like ICPC-coded morbidity.

**Example of prognostic research in the JGPN**
Bertens et al. developed a prediction model for exacerbations in patients with COPD [39].

**Intervention studies**
Randomized controlled trials (RCTs) are difficult to perform within a cohort of observational routine care data, but as an alternative, a case-control design could be used to evaluate an intervention. Patients cannot be included through randomisation, but sampling techniques can be applied to limit selection bias while selecting controls. In addition, quasi-experimental designs can be used to evaluate interventions, including pre-post comparisons or stepped wedge designs for introduction of innovations in a ‘real life’ setting. To validate the effect, information on potential confounders is needed, otherwise, the validity of the outcomes of these types of studies is hampered.

**Example of intervention research in the JGPN**
Vennekamp et al. conducted a study in which a recent update of a primary care guideline on acute rhino sinusitis (ARS) was evaluated. The judicious use of antibiotics by consultation and prescription rates before and after the introduction of the guideline were compared [40].

**Quality of care support and development of health care innovations using the JGPN**
Routine primary care data also provide the opportunity for quality support and evaluation of health care innovations. For these ‘interventions’ it is essential the GP receives feedback information on patient level. To enable this, data need to be de-anonymised. The patient’s own GP is the only person having the key to identify his/her patients again.

**Patient selections for ‘patients at risk’**
The principle of ‘panel management’ is that routine care data are used to preselect (symptomatic or asymptomatic) people at risk of a disease. Selected high-risk patients may subsequently be approached by the GP for preventive interventions. The selection frequently requires a priori prognostic research to identify which combination of risk factors optimally predicts the development of a disease [41]. Once the risk profile is identified it can be applied to the JGPN dataset, and participating practices subsequently receive a list of high-risk patients that need to be approached for
follow-up actions. In this way, “real time” monitoring and feedback can be offered within the JGPN network.

**Example of selection of patients at risk management in the JGPN** In the U profit study Drubbel et al. developed a frailty index (FI) for elderly patients that calculates the patient’s risk of frailty based on the patient’s health characteristics and health care consumption. To predict adverse health outcomes, survival curves were constructed and hazard ratios estimated. The FI for all elderly patients in the JGPN were calculated, and patients at risk were reported to the GP, who then could actively approach the patient for care interventions [42].

**Support in individual patient management**
JGPN can also be used to support daily clinical practice by adding (anonymously) new clinical information to the medical files of patients. The researcher may review the routine care data of the GP and (re)calculate the reliability of a particular diagnosis based on the characteristics and clinical data of a patient. Confirmation or cancellation of the diagnosis or new diagnosis is returned (in encrypted form) to the practice to enrich the GPs’ registration and to upgrade the patients’ records.

**Example of individual patient management in the JGPN**
Van Doorn cs. were focussing on the management of atrial fibrillation (AF). Patients with an ICPC code K78 ‘atrial fibrillation/flutter’ were checked for a confirmatory 12-lead electrocardiogram or heart rhythm registration, and the CHA2DS2-VASc risk score was calculated in every case with confirmed AF. This information was fed back to the GPs. With this information, the GP could re-consider the antithrombotic management of the patients with AF [43].

**Quality evaluation programs on population level**
The JGPN database can also be used for the evaluation of new disease managing care programmes. For example, the introduction of a new guideline may be evaluated by comparing pre and post outcomes such as referral patterns or prescription trends. To select a patient cohort that receives the guideline or managed care programme, arrangements must be made with the GPs concerned. In this type of study the effect on the outcome must be defined by the intervention components, after control for possible confounders such as practice variability. Studies monitoring antibiotic prescriptions are striking examples, such as the study evaluating the introduction of an update of the guideline on acute rhino sinusitis [40].

**Example of quality evaluation in the JGPN**
Van den Broek d’Obrenan described the antibiotic management of infectious diseases in the JGPN. During 2007–2010 all contacts for infections and the rate and choice of antibiotics in 45 practices were analysed [44].

The use of the JGPN data for educational purposes in GP specialty training
If GP trainees are trained in one of the practices participating in JGPN the routine care data can be used for assessing educational progress by monitoring clinical performance. An important condition is that trainees have their own login code to register their patient contacts in the electronic medical files. Analysing these registrations provides excellent opportunities for monitoring the patient’s mix that GP trainees see, as well as their clinical performance, and trainees can evaluate their performance with their supervisors [45]. The medical management decisions of the trainee can be evaluated against key indicators of professional guidelines. Kortekaas et al. developed a program of key indicators for 27 clinical practice guidelines [46]. Compliance with these indicators can be evaluated using data extracted from the JGPN routine care registration. This system needs further refinement but can provide supportive feedback reports for trainees and their supervisors during the GP specialty training [47].

**Discussion**
Routine-care primary care databases such as the JGPN offer excellent potential for different types of clinical research. In addition, the database can be used for feedback and monitoring purposes in support of quality of care programs in daily care. In future the dataset will also be used for educational purposes, to monitor the clinical performance of GP trainees and medical students in primary care practice. Important assets of the JGPN are the size of the data set, the length of the follow-up, the representativeness of its population, and the variety of clinical information that is registered. Much effort has been put in uniformity of the registration of the routine care, resulting in a high accuracy of the data over the years.

**Comparison with other data networks**
Many primary care routine datasets exist; most are used only for research purposes. In the Netherlands, for example, all academic universities have such a (research) network. In the UK the General Practice Research Database is focused on facilitating larger scale observational research in primary care. Other networks have surveillance or monitoring purpose, such as the LINH sentinel network of NIVEL in the Netherlands that provides representative (monitoring) data on morbidity and clinical management in primary care. The content and the quality of the data vary between different databases. Some networks only store the coded information, and do not extract the qualitative text data, laboratory results, or the referral letters. The quality mainly
depends upon the uniformity in coding, the training that participating GPs received, and the frequency of extrac-
tions. Some networks provide extensive training sessions, 
while others largely depend on routine data entry in the 
participating practices. The JGPN offers several advantages 
over other networks: it stores information on all aspects of 
clinical care; qualitative textual information on reason for 
encounter, diagnostic data, ICPC coded diagnoses and ATC 
coded prescription data, and referrals and return letters 
from specialists. Participating GPs are used to working with 
a structured coding program. The JGPN is based on a 
long-standing collaboration between regional participants 
and the academic department, and the practices actively 
participate in the management and exploitation of the data-
base. Finally, the JGPN dataset is used for various objec-
tives: not only for academic research, but also for regional 
surveillance, managed care programs and quality bench-
marking purposes as well for educational purposes. This 
supports the feeling of joint ownership and creates a ‘win-
win’ with participating practices.

Limitations of the database
The JGPN database contains observational data, of the 
consultations that were registered by the GP, depending 
on the interpretation of the consultations by the GP and 
the way it was registered by the GP. This is also the limi-
tation of the dataset. Because of the anonymous charac-
ter, it is not possible to go back to the patient in order 
to collect additional information. Additional information 
becomes available only if the patient reappears on con-
sultation, or if data are linked to other sources. Missing 
data for specific research questions are not retrievable.

A second limitation of the data is that follow-up may 
be interrupted by both moving or by death. With the re-
moval of patients from the database, the distinction be-
tween those who moved or those who passed away is no 
longer traceable. Through proxy indicators on morbidity 
or through linkage to the official death registry (CBS) 
this limitation can often be overcome.

A third limitation is that the detailed data of the elec-
tronic chronic disease management programs, that many 
practice have introduced to monitor their patients with 
type 2 diabetes, chronic obstructive pulmonary disease, 
and cardiovascular risk management, were initially not 
amatically transferred to the routine care registration. 
Thus, these data were not available in JGPN. In recent 
years however, key indicators of chronic disease manage-
ment programs are automatically copied to the routine 
care registration.

Finally, data extraction takes place only four times a 
year, so the data are not always up to date. Given the 
progress in data capturing techniques, however, a system 
of real-time monitoring should be realistic in the future.

Suitability for research; pros and cons
The longitudinal character of the database provides the 
opportunity to perform observational analyses in different 
designs. Etiological studies can be achieved by splitting up 
the cohort and compare the positive and negative 
study-arm adjusting for the potential confounders. In 
addition, the database is large enough to analyse matched 
groups who are matched on important characteristics. 
The presence of additional determinants such as disease 
history, signs and test results make the data also attractive 
for prognostic studies. Diagnostic studies are more difficult 
to perform as test results are incompletely entered in the 
database. This can be overcome by linking individual data 
from laboratory databases. Interventions can be evaluated, 
but only in observational comparisons, with quasi experi-
mental designs. This is particularly effective in the evalu-
ation of healthcare innovations or guidelines after introd-
uction on population level.

One could argue that JGPN contains insufficient per-
formance indicators for monitoring quality of care, since 
GP practices vary in the level of detail of information 
that is entered in the routine care registration. As a re-
result, indicators of quality of care cannot always ad-
equately be generated. These limitations, however, can 
be overcome in two ways. First, many clinical outcomes 
can be estimated by the use of proxy indicators, such as 
referrals (for treatment), or medication (for diagnosis). 
These proxy indicators have intrinsic limitations because 
of, for example, inter-physician variation in referrals or 
in individual health policies. Alternatively, clinical infor-
mation can be enriched by linkage to other databases, 
such as those from hospitals, insurance companies or 
from disease-specific registries. Even when a determinis-
tic or probabilistic linkage would result in a number of 
unidentified individuals, the number of patients in the 
JGPN is large enough to have adequate statistical power.

Future challenges
The main future challenges for JGPN are the develop-
ment of a regional data warehouse, the need to ade-
quately address the medical ethical legislation for large-scale routine care data collection and the need to 
safeguard the commitment of partners such as GPs and 
patients. JGPN was initially setup as a mono disciplinary 
registration network. However, for optimal use of the 
data in future, structural linkage to other sources is es-
ential to meet the ever- increasing demands of re-
searchers, to continuously upgrade the quality of the 
data and to broaden the scope of the database. Recently, 
linkage to laboratory data, disease registries, and hospital 
data proved successful, but time consuming. In future, 
real-time linkage through a virtual regional data ware-
house, connecting all relevant data sources in the region, 
should overcome these limitations.
Legislation around medical databases is becoming more strict, to protect the privacy of patients and medical professionals. Many suggest that individual informed consent is required for optimal protection, but experience has learnt that only a minority of patients do respond to requests for research participation. This would threaten both the size of the database as well as its representativeness. The present opt out procedure, with optimal information provision in the practices, a register of patients that refuse to participate, and shared governance over the data, adequately safeguards ethical use of the data. Ultimately, it is the patient, and not the professional or the researcher, that decides on the use of the individual health data, even though they are anonymised. Therefore not only researchers and GPs, but also patients should be actively involved in the JGPN steering committee. Patient participation is therefore one of the challenges for the near future.

Conclusions
Routine-care primary care databases such as the JGPN offer excellent potential for different types of clinical research. Moreover, such databases can be used to support quality management in participating practices, thus optimizing individual patient care. This secures the balance between academic interest, and value for the participating GPs and patients, stimulating the concept of joint ownership, and turning a database into a solid instrument in regional health care developments.

Acknowledgements
We thank all GPs participating in the JGPN, and all visionary academics of the past who initiated the data collection. Information about the JGPN is to be found on http://portal.juliuscentrum.nl/research/nl-nl/cohortsandprojects/cohortsprojects/juliusgeneralpractitionersnetwork/jhn.aspx

Availability of data and materials
Unfortunately, the raw data cannot be made publicly available due to ethical and legal restrictions, as also stated in paragraph 2.2.5, privacy issues. However, all interested readers may request data from Dr. Marlous Kortekaas (m.f.kortekaas@umcutrecht.nl), the study coordinator of the JGPN.

Authors’ contributions
HMS was the primary investigator of this study and (1) designed the study, (2) acquired the data, (3) analysed the data, and (4) interpreted the data; (5) drafted the article; and (6) approved of the final version to be published. CWH and MFK (2) acquired data, (3) analysed the data, (4) interpreted the data, (5) revised the article critically for important intellectual content; and (6) approved of the final version to be published. Wydk, GD, HS-P, AWH, and NJ-W. (1) made substantial contributions to conception and design of the study, (5) have been involved in revising the manuscript critically for important intellectual content; and (6) approved of the final version to be published.

Authors’ information
All authors work at the Julius Centre or work as a GP and have been involved in the JGPN for quite some years.

Ethics approval and consent to participate
Research in the Julius General Practitioners’ Network is observational, without an intervention, and enlisted patients are not individually approached for participation. Therefore, the Medical Ethics Committees in the Netherlands do not rank such research as subject to the Dutch ‘Wet medisch-wetenschappelijk onderzoek’ (WMO: Medical Research Involving Human Subjects Act), but researchers need to conform to privacy legislation. The complete pseudonymised dataset is stored safely, and only copies of parts of it are delivered to researchers after they have requested it and the Julius General Practitioners’ Network has agreed on executing their research proposal. Such data sets are made only available under the strict condition of anonymity, and researchers have to give written consent to destroy the data at the end of their study. In the data linkage process privacy is ensured by the so-called pseudonymisation procedure; linkage codes are destroyed after successful data linkage.

Consent for publication
Not Applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, P.O. Box 85500, 3508, GA, Utrecht, The Netherlands. 2General practice De Grebbe, Rhenen, The Netherlands. 3General practice Mariahoek aan de Singel, Utrecht, The Netherlands. 4General practice Health Centre De Bilt, De Bilt, The Netherlands. 5General practice Health Centres Leidsche Rijn, Utrecht, The Netherlands.

Received: 7 December 2017 Accepted: 7 September 2018
Published online: 25 September 2018

References
1. Anderson JE. Reliability of morbidity data in family practice. J Fam Pract. 1980;10:677–83.
2. Coulter A, Brown S, Daniels A. Computer held chronic disease registers in general practice: a validation study. J Epidemiol Community Health. 1989 Mar;43(1):25–8.
3. Huygen FJA. Family medicine; the medical life history of families. Nijmegen: Dekker & Van de Vegt; 1978.
4. Morris L, Taylor M, Campbell LM, Sullivan FM. How will practices cope with information for the new GMS contract? Coronary heart disease data recording in five Scottish practices. Inform Prim Care. 2003;11(3):121–7.
5. De Jongh H, Kole H, JFM M, Peeren J, Smit C, Stroucken J, et al. Richtlijn adequate dossiervorming met het Elektronisch Medisch Dossier. NHG-publicatie automatisering. Utrecht: Nederlands Huisartsen Genootschap; 2004.
6. Søler JK, Oldes I, Wood M, Lamberts H. The coming of age of ICPC: celebrating the 21st birthday of the international classification of primary care. Fam Pract. 2008;25:312–7.
7. Vandenbergroucke JP. When are observational studies as credible as randomised trials? Lancet. 2004;363:1728–31.
8. Visscher S, Veen P ten, Verheij R. Kwaliteit van ICPC-codering. Huisarts Wetensch. 2012;55:459.
9. Jordan K, Porcheret M, Croft P. Quality of morbidity coding in general practice computerized medical records: a systematic review. Fam Pract. 2004;21:396–412 Review.
10. Häyrinen K, Saranto K, Nykänen P. Definition, structure, content, use and impacts of electronic health records: a review of the research literature. Int J Med Inform. 2008;77:291–304.
11. Lix LM, Walker R, Quan H, Nisole 32 D, Yang J, Chen G, CHES-ORTF hypertension outcomes and surveillance team. Features of physician services databases in Canada. Chronic Dis Inj Can. 2012;32:186–93.
12. Schers H, Bor H, van den Hoogen H, van Weel C. What went and what came? Morbidity trends in general practice from the Netherlands. Eur J Gen Pract. 2008;14(Suppl 1):13–24.
13. Van Weel C. The continuous morbidity registration Nijmegen: background and history of a Dutch general practice database. *Eur J Gen Pract*. 2008;14(Suppl 1):5–12.

14. Lamberts H. The international classification of health problems in primary care and a new patient record for family practice. Dutch Huisarts Wet 1975;18:165–7.

15. Lambert H. In het huis van de huisarts. Verslag van het Transiteproject. 288 bl., fig., tabellen. Mededekte, Lelystad 1991. ISBN 90-5070-013-6.

16. Lambert H, Brouwer HJ, Mohrs J. Reason for encounter- episode- and process oriented standard output from the transition project. Parts I and II. Amsterdam: Department of General Practice University of Amsterdam, 1991.

17. van der Velden J, Bakker DH, Clesaens AAMC, Schellevis FG. Een national studie naar zieken en verrichtingen in de huisartspraktijk. Utrecht: Nivel; 1991.

18. Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all infants against pneumococcal infection cost effective? Evidence from a Dutch general practice based clinical prospective cohort study in Utrecht, the Netherlands. J Epidemiol Community Health. 1998 Feb;52(1):1–5.

19. van den Dungen C, Hoeymans N, Bosshuizen HC, van den Akker M, Bijmans MC, van Boeijen K, Brouwer HJ, Verheij RA, de Waal WM, Schellevis FG, Westert GP. The influence of population characteristics on variation in general practice based morbidity estimations. *BMJ Public Health*. 2011;11:887.

20. van den Dungen C, Hoeymans N, Schellevis FG, van Oers HJ. Quality aspects of Dutch general practice-based data: a conceptual approach. *Fam Pract*. 2013;30:355–61.

21. Kole HM, Metzmakers JM, Smit C, Stroocean JM (Schooler FCMW), Njoh KH (Red). NHG Richtlijn Adequate dossiervoering met het EPD (ADEXE) Aanvulling over episodes. Nederlands Huisartsen Genootschap Utrecht 2009.

22. van den Dungen C, Hoeymans N, Gijzen R, van den Akker M, Boesten J, Brouwer H, Smeets H, van der Veen WJ, Verheij RA, de Waal M, Schellevis F, Westert G. What factors explain the differences in morbidity estimations among general practice registration networks in the Netherlands? A first analysis. *Eur J Gen Pract*. 2008;14(Suppl 1):53–62.

23. van Weel C. Longitudinal research and data collection in primary care. *Ann Fam Med*. 2005;3(Suppl 1):546–51.

24. Manuel DG, Rosella LC, Stukel TA. Importance of accurately identifying cancer diagnoses in studies using electronic health records. *BMJ*. 2010;341:c4226.

25. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. *Br J Clin Pharmacol*. 2011;65(1):537–46.

26. van Walraven C, Austin PC, Manuel D, Knoll G, Jennings A, Forster AJ. The usefulness of administrative databases for identifying disease cohorts is increased with a multivariate model. *J Clin Epidemiol*. 2010;63:1332–41.

27. Nijdam ME, Timmerman MR, Franx A, Bruurse HW, Numans ME, Grobbee DE, Bots ML. Cardiovascular risk factor assessment after pre-eclampsia in primary care. *BMJ Fam Pract*. 2009 Dec;59(12):7167. doi:10.1136/jnep.2010.077777.

28. Sollie A, Szimons RH, Helper J, Numans ME. Reusability of coded data in the primary care electronic medical record: a dynamic study cohort concerning cancer diagnoses. *Int J Med Inform*. 2016;99:45–52. https://doi.org/10.1016/j.ijmedinf.2016.08.004.

29. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis health database. *J Clin Epidemiol*. 2011;64:247–50.

30. Lacourt TE, Houthoorn JH, Smeets HM, Lipovsky MM, van Doornen LJ. Infection load as a predisposing factor for somatof orm disorders: evidence from a Dutch general practice registry. *Psychosom Med*. 2013;75:759–64.

31. Sollie A, Helper J, Ader R, Aron R, Numans ME, van der Wouden JC, Numans ME. Primary care management of women with breast cancer-related concerns—a dynamic cohort study using a network database. *Eur J Cancer Care (Engl)*. 2016;25:1005–14.

32. Tim. http://www.tm7.eu. Last visited 20 June 2018.

33. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol*. 2005;58:323–37 Review.

34. Van Der Elst AM, Verheij TJ, Rovers MM, Veenhoven RH, Groenwald RH, Bonten MJ, Sanders EA. Trends in primary-care consultations, comorbidities, and antibiotic prescriptions for respiratory infections in the Netherlands before implementation of pneumococcal vaccines for infants. *Epidemiol Infect*. 2012;140:823–34.